TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Shaughnessy JD; Zhou Y; Haessler J; van Rhee F; Anaissie E; Nair B; Waheed S; Alsayed Y; Epstein J; Crowley J; Barlogie B; British Journal Of Haematology, 2009, vol. 147, issue 3, p 347, ISSN 13652141. ISBN 13652141.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef